SSIEM 2024 symposium: Unlocking new possibilities in phenylketonuria
This symposium, presented at SSEIM 2024, provides an overview of sepiapterin as a potential treatment for phenylketonuria (PKU) and its implications for patient management
Recognize the unmet needs in PKU and how patient care is managed
Learn more about sepiapterin as a potential treatment for PKU
Understand the mechanism of action of sepiapterin
Sepiapterin is an investigational product currently in development for PKU.
This symposium was developed and funded by PTC Therapeutics for SSIEM 2024.
Register now to unlock the content
Register now to access the content on this page
Already registered?
If not, register below
MED-ALL-PKU-2400224 | October 2024
Sign in or register to access exclusive content on this site
Register here to access the content on the site MED-ALL-CORP-2200029 | October 2023
You are now leaving MEDhub, a website provided by PTC Therapeutics. This link will take you to a website to which our Privacy Statement and our Terms and Conditions do not apply.
We encourage you to read the Privacy Policy and the Terms and Conditions of every website you visit. PTC Therapeutics does not endorse and/or influence the content found on websites not owned/operated by PTC Therapeutics.
The content you are trying to access is not currently available.
We will be updating the MEDhub site regularly to provide you with up-to-date, insightful expert-led content. To be notified when new additions become available, register now.